Pharmacy benefit managers (PBMs) significantly impact GTN revenue through rebates, but patient access issues persist due to ...

In mid-November, to boost domestic drug product manufacturing of its own, Moderna announced 3 a new $140 million investment ...

The evolution from time-consuming manual reviews to automated detection and now to intelligent action is reimagining the ...

In today’s Pharma Pulse, SOBI strengthens its gout franchise by acquiring Arthrosi Therapeutics for up to $1.5 billion, ...

Cheryl Allen, BS Pharm, MBA, founding partner, highlights the coming year's focus on navigating an evolving regulatory ...

AI-powered control towers and digital twins are emerging as essential tools to prevent costly supply chain failures and restore operational reliability.

At a time when investors are questioning the sustainability of pharmaceutical business models, reliable execution has become ...

Although he typically revises his macro framework only once every decade or more, Roth explained that the current environment ...

Modern PBMs, or PBM-like functions, should operate with full line-of-sight to net price and patient outcomes. Full ...

One of which revolved around “Optimizing GTN Strategy—Balancing Channel Economics and Market Access,” led by Lannett ...

In today’s Pharma Pulse, the FDA approves Amgen’s Uplizna (inebilizumab-cdon), the first CD19-targeted therapy for gMG with convenient twice-yearly dosing, and much more.

How pharma can productively coexist with PBMs—and still lower drug costs faster.